xSW579 Xenograft Model Overview
The xSW579 xenograft model is derived from a human papillary thyroid carcinoma (PTC) cell line, xSW579, which was established from a primary tumor in a patient with differentiated thyroid carcinoma (DTC), specifically the papillary subtype. Papillary thyroid carcinoma is the most common type of thyroid cancer, characterized by slow growth and a generally favorable prognosis. However, it can still present significant challenges in terms of metastasis, particularly to the lymph nodes and lungs, and may exhibit resistance to standard treatments like radioactive iodine (RAI) therapy. The xSW579 xenograft model provides a valuable tool for preclinical research focused on thyroid cancer, offering insights into tumor biology, metastasis, and therapeutic resistance. Its ability to replicate key features of PTC, including genetic mutations and receptor profiles, makes it an ideal platform for evaluating novel therapeutic strategies, including targeted therapies, immunotherapies, and combination treatments.
Request a Custom Quote for xSW579 Xenograft ModelBiological and Molecular Characteristics
xSW579 cells are characterized by their thyroid-specific origin, expressing markers such as thyroglobulin (TG) and sodium-iodide symporter (NIS), which are involved in iodine uptake in thyroid cells. Additionally, these cells harbor specific mutations commonly found in papillary thyroid carcinoma, such as the BRAF V600E mutation, which is a key driver of tumorigenesis in many cases of PTC. The BRAF mutation leads to the constitutive activation of the MAPK/ERK signaling pathway, driving tumor cell proliferation, survival, and invasion. In addition to BRAF mutations, xSW579 cells show overexpression of vascular endothelial growth factor (VEGF), a potent angiogenesis factor that supports tumor growth. These molecular characteristics make the xSW579 xenograft model particularly valuable for studying therapies aimed at inhibiting the MAPK/ERK pathway, VEGF, and other signaling pathways involved in thyroid cancer progression.
| Marker | Expression Level | Function |
|---|---|---|
| Thyroglobulin (TG) | High | Thyroid-specific marker |
| Sodium-Iodide Symporter (NIS) | High | Essential for iodine uptake in thyroid cells |
| BRAF (V600E) | Mutated | Oncogene driving tumorigenesis and resistance |
| VEGF | Elevated | Promotes angiogenesis and tumor growth |
In Vivo Model Development and Tumorigenicity
The xSW579 xenograft model is typically developed by implanting xSW579 cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Following implantation, the cells form tumors that closely replicate the clinical features of papillary thyroid carcinoma, including the presence of thyroid-specific markers such as thyroglobulin and NIS. These tumors exhibit high cellularity, significant vascularization, and areas of necrosis, indicative of rapid tumor growth. The xSW579 model is particularly useful for evaluating the effects of chemotherapy agents, radioactive iodine (RAI) therapy, and targeted therapies, such as BRAF inhibitors, which specifically target the BRAF V600E mutation and the associated MAPK/ERK signaling pathway.
In addition to subcutaneous implantation, orthotopic models of xSW579 can be established by implanting the cells directly into the thyroid gland of immunocompromised mice. This orthotopic model more accurately mimics the natural site of tumor growth, allowing for the study of local invasion, metastasis, and the effects of treatment on the tumor microenvironment. The ability of xSW579 tumors to metastasize to distant organs, including the lungs and lymph nodes, makes the model ideal for studying metastatic disease and evaluating therapies aimed at preventing or treating metastasis in thyroid cancer.
Request a Custom Quote for xSW579 Xenograft ModelHistopathology and Immunohistochemical Profile
Histopathological analysis of xSW579 xenografts reveals the characteristic features of papillary thyroid carcinoma, including well-defined follicles, eosinophilic cytoplasm, and nuclear features such as overlapping nuclei with nuclear grooves, a hallmark of PTC. The tumors also exhibit areas of necrosis due to the rapid tumor growth. Immunohistochemical staining of xSW579 xenografts shows strong expression of thyroglobulin (TG) and sodium-iodide symporter (NIS), confirming the thyroid origin of the tumors. BRAF V600E mutations can be detected using specific probes, which highlight the role of this oncogene in driving tumor progression in PTC. Additionally, elevated levels of VEGF are observed, suggesting the importance of angiogenesis in sustaining tumor growth. The tumors also show high levels of phosphorylated ERK, indicating the activation of the MAPK/ERK signaling pathway, which promotes cell survival, proliferation, and metastasis. CD31 staining reveals significant vascularization, reflecting the importance of blood vessel formation in supporting tumor growth.
Preclinical Applications and Drug Response
The xSW579 xenograft model is widely used to evaluate the efficacy of various therapeutic agents for thyroid cancer. The model is particularly useful for testing chemotherapy agents, radioactive iodine (RAI) therapy, and targeted therapies, such as BRAF inhibitors (e.g., vemurafenib), which target the BRAF V600E mutation and the associated MAPK/ERK signaling pathway. Given the model’s potential to develop resistance to RAI therapy and chemotherapy over time, it is highly valuable for studying the mechanisms of therapy resistance and testing new agents that may overcome these challenges.
In addition to chemotherapy and targeted therapies, the xSW579 xenograft model is increasingly used to assess the potential of immunotherapies, including immune checkpoint inhibitors and monoclonal antibodies targeting tumor-specific antigens. The model’s ability to replicate the key features of papillary thyroid carcinoma, including aggressive growth, metastasis, and resistance to therapy, makes it an ideal system for studying new treatment strategies. Furthermore, the ability of xSW579 xenografts to metastasize to distant organs provides an excellent opportunity to evaluate therapies aimed at preventing or treating metastatic disease in thyroid cancer.
Request This Model
To request the xSW579 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for xSW579 Xenograft Model